Allergic rhinitis affects millions of children and adults. Indeed, it is the fifth most common chronic disease in the United States. Although people do not die from allergic rhinitis, it sure can make you feel miserable, disturb sleep, and impair daily activities. Guidelines recommend the use of intranasal corticosteroids on a daily basis since the onset of action takes a few days. In reality, however, patients adjust their treatment according to the severity of their symptoms. As-needed corticosteroid use is effective for the treatment and prevention of asthma symptoms. Can we apply this same concept to allergic rhinitis? Could the as-needed use of intranasal corticosteroids achieve the same outcomes as daily use?
Guest Authors: Lalitha Sukumar, PharmD; Alyssa Gallipani, PharmD, BCACP; and Rahul Jacob, PharmD
Music by Good Talk
The Generic Levothyroxine Conundrum
Is Icosapent Ethyl a QALY-ty Investment?
Level Up! An Abstinence Game for Smoking Cessation
Breaking the SABA-only Rescue Habit: Two Drugs Are Better Than One
Are You Sure? Tolerance of Uncertainty and the Risk of Stress-Related Harm
Top Ten Things Every Clinician Should Know About the 2022 Heart Failure Guidelines
SAGE Wisdom: Analysis of a Self-Administered Gerocognitive Test
Educating Patients and Prescribers About Deprescribing to Reduce Medication Burden May Not Be Enough
Treating mild hypertension during pregnancy: Time for a new CHAPter!
Finally! Something FDA-Approvable for Non-alcoholic Steatohepatitis (NASH)?
Managing Pain in Patients with High Blood Pressure: Is There No Safe PATH?
Continuous Glucose Monitors (CGMs) - Patient Management Strategies and Getting Paid!
A Healthier Way to Commute? Cycling Reduces Mortality in Patients with Diabetes
Annual Wellness Visits: Pharmacists Closing Care Gaps
FOMO — Keeping Up With the Primary Literature
Could a DOAC Replace Warfarin to Treat the Thrombotic Antiphospholipid Syndrome?
The Top Ten Things Every Clinician Should Know About Sacubitril/Valsartan
Don’t Miss a Beat: The Importance of Influenza Vaccination in Patients with Coronary Disease
Why is Thor’s Hammer, Molnupiravir, Considered a 4th Line Option for COVID-19?
Top Ten Things Every Clinician Should Know about the 2022 Medical Standard of Care for Diabetes
Create your
podcast in
minutes
It is Free
Good Mood Revolution
The Relaxback UK Show
On Call With Dr. Anselm Anyoha
Precision Medicine Forum Podcast
The Doctor’s Farmacy with Mark Hyman, M.D.
The Peter Attia Drive